Chuck DeWildt
About Chuck DeWildt
Chuck DeWildt is the Chief Commercial Officer at Neurelis, with over 25 years of experience in leadership roles across the pharmaceutical and biotechnology sectors, specializing in CNS, respiratory, and oncology markets.
Title: Chief Commercial Officer
Chuck DeWildt holds the title of Chief Commercial Officer at Neurelis, a role he has served in since 2019. DeWildt initially joined Neurelis in early 2018 as the Senior Vice President of Commercial and Market Access and has since been elevated to his current position. His extensive experience in leadership within sales, marketing, and market access has been instrumental in his role.
Leadership Roles in Pharmaceutical and Biotechnology
With over 25 years in the pharmaceutical and biotechnology industry, Chuck DeWildt has extensive experience in various leadership roles encompassing sales, marketing, and market access. His career spans significant contributions in the CNS, respiratory, and oncology markets. His approach to leadership focuses on leveraging commercial strategies to enhance market access and sales performance.
Professional Experience at Neurelis
In early 2018, Chuck DeWildt joined Neurelis as the Senior Vice President of Commercial and Market Access. His effectiveness in this role led to his promotion to Chief Commercial Officer in 2019. During his tenure at Neurelis, DeWildt's strategic initiatives have been pivotal to the company's commercial operations, especially in the niche markets of CNS and related fields.
Previous Role at Teva Pharmaceutical Industries
Before joining Neurelis, Chuck DeWildt was Vice President of Market Access at Teva Pharmaceutical Industries Ltd. He joined Teva in 2011 as part of their acquisition of Cephalon, where he served as the Head of Market Access and Reimbursement. His role at Teva cemented his expertise in navigating complex market access landscapes.
Early Career at DuPont and Cephalon
Chuck DeWildt began his pharmaceutical career at DuPont, where he developed foundational industry skills. In 1999, he transitioned to Cephalon, where he advanced to head the Market Access and Reimbursement division. His tenure at Cephalon equipped him with critical insights and expertise that he carried forward into his subsequent roles in the pharmaceutical and biotechnology sectors.